{"id":68777,"date":"2026-06-30T13:14:25","date_gmt":"2026-06-30T11:14:25","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/06\/30\/distinct-lymphocyte-immune-signatures-to-nivolumab-and-recombinant-il-7-ex-vivo-in-patients-with-sepsistimothy-arthur-chandos-snow-on-30-de-june-de-2026-at-1000\/"},"modified":"2026-06-30T13:14:25","modified_gmt":"2026-06-30T11:14:25","slug":"distinct-lymphocyte-immune-signatures-to-nivolumab-and-recombinant-il-7-ex-vivo-in-patients-with-sepsistimothy-arthur-chandos-snow-on-30-de-june-de-2026-at-1000","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/06\/30\/distinct-lymphocyte-immune-signatures-to-nivolumab-and-recombinant-il-7-ex-vivo-in-patients-with-sepsistimothy-arthur-chandos-snow-on-30-de-june-de-2026-at-1000\/","title":{"rendered":"Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis\u200bTimothy Arthur Chandos Snow   on 30 de June de 2026 at 10:00"},"content":{"rendered":"<div>\n<p><b>J Leukoc Biol<\/b>. 2026 Jun 8;118(6):qiag057. doi: 10.1093\/jleuko\/qiag057.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Therapeutic modulation of sepsis-induced immune dysfunction by targeting lymphocyte dysfunction with recombinant IL-7 (rIL-7) and anti-PD-1 (e.g. nivolumab) has shown promise in preclinical and early clinical studies. Prior to conducting large randomized controlled trials, an in-depth understanding of the changes induced by rIL-7 or nivolumab (and their differences) in patients with sepsis is imperative. We performed a prospective observational cohort study including patients admitted to the intensive care unit with sepsis and characterized their T lymphocyte phenotype using flow cytometry. The ability of T lymphocytes to respond to a stimulus (using anti-CD3\/CD28 beads) and the effect of rIL-7 or nivolumab on T lymphocyte immunophenotype ex vivo was assessed. In a cohort of 55 patients, CD4+ and CD8+ T lymphocyte PD-1 was higher and IL-7R lower compared with healthy volunteers. In a subset of 24 intensive care unit patients in whom in-depth immunophenotype was characterized, ex vivo response of lymphocytes to anti-CD3\/CD28 beads was reduced compared with healthy volunteers, simultaneously inducing features consistent with immune activation and immunosuppression. rIL-7 was associated with a greater spectrum of changes compared with nivolumab. The response to rIL-7 and nivolumab was influenced by anti-CD3\/CD28 bead costimulation. rIL-7 and nivolumab elicited distinct T lymphocyte responses ex vivo, and the changes were influenced by T lymphocyte activation. It needs to be determined if similar changes occur in vivo, which may influence the choice of immunomodulatory therapy in sepsis.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42376746\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=8405628&amp;ff=20260630071424&amp;v=2.20.0\">42376746<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jleuko\/qiag057\">10.1093\/jleuko\/qiag057<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Leukoc Biol. 2026 Jun 8;118(6):qiag057. doi: 10.1093\/jleuko\/qiag057. ABSTRACT Therapeutic modulation of sepsis-induced immune dysfunction by targeting lymphocyte dysfunction with recombinant IL-7 (rIL-7) and anti-PD-1 (e.g. nivolumab) has shown promise in preclinical and early clinical studies. Prior to conducting large randomized controlled trials, an in-depth understanding of the changes induced by rIL-7 or nivolumab (and &#8230; <a title=\"Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis\u200bTimothy Arthur Chandos Snow   on 30 de June de 2026 at 10:00\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/30\/distinct-lymphocyte-immune-signatures-to-nivolumab-and-recombinant-il-7-ex-vivo-in-patients-with-sepsistimothy-arthur-chandos-snow-on-30-de-june-de-2026-at-1000\/\" aria-label=\"Read more about Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis\u200bTimothy Arthur Chandos Snow   on 30 de June de 2026 at 10:00\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86,42],"tags":[],"class_list":["post-68777","post","type-post","status-publish","format-standard","hentry","category-journal-of-leukocyte-biology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/68777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=68777"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/68777\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=68777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=68777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=68777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}